About Us
Advancing Non-Invasive Healthcare
In 2015 Nonacus was founded with a singular purpose: to offer high quality, non-invasive, genetic testing with the end-user at the forefront. Formed by a dedicated group of biotechnology professionals with over 35 years of experience within the sector, Nonacus understands the need for laboratories to continually deliver progress. This understanding forms the basis of all our products and drives our innovation.
Our Mission and Purpose
Our Mission
Our goal is to democratize non-invasive genetic testing globally with a focus on oncology so that we can enable decentralized, cost-effective and cutting-edge cancer detection and longitudinal patient monitoring.
Our Purpose
Detecting cancer earlier and informing patient outcomes through the deployment of a truly innovative liquid biopsy testing platform.
The Nonacus Name
When Chris and Lee founded Nonacus in 2015 they had a singular purpose - to develop non-invasive DNA tests that would change the way genomic diagnostics was done.
Choosing a name that would reflect this mission wasn't easy.
Based off the Latin term ‘non acus’ meaning ‘no needle’, Nonacus accurately symbolises the company’s mission- to move away from intrusive, risky diagnostic procedures like tissue biopsies or amniocentesis towards less invasive testing. To read more about the story behind the name click here.
ISO 13485:2016 Certification
At Nonacus, we are deeply committed to delivering unparalleled quality and precision in biotechnology.
Our dedication to excellence is underscored by our ISO 13485:2016 BSI certificate, an internationally recognized standard for medical device quality management.
Read Our Latest Insights
The NEW sample-to-report NGS bladder cancer test: GALEAS Bladder – All you need to know
To improve bladder cancer management for both patients and clinicians, Nonacus developed and launched GALEAS Bladder. This urine-based molecular biomarker test is highly accurate and sensitive at detecting all stages and grades of bladder cancer. It provides a simple sample-to-report, molecular triage for patients with hematuria; streamlining the clinical diagnosis process and reducing the need for cystoscopies.
Read More
To consolidate multiple testing strategies for haematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia
To help consolidate multiple testing strategies for haematological malignancies, our customer designed a Nonacus NGS panel, creating the first NGS workflow for both myeloid and lymphoid neoplasia.
Read More
Detecting copy number variants using Next Generation Sequencing
Copy number variants are responsible for 5-10% of genetic disease – that’s why detecting them reliably and robustly is so important in clinical labs. Next Generation Sequencing panels have proven to be extremely useful for clinical applications and can successfully detect many genomic variants, but they can often struggle with CNV detection.
Read More